We asked UK consumers about "Prevalence of health conditions" and found that *************************************************************** takes the top spot, while ********************************************************************** is at the other end of the ranking.These results are based on a representative online survey conducted in 2025 among 6,176 consumers in the UK.

Disease prevalence and achievement/exception performance against key indicators for GP Practices as part of the Quality and Outcomes Framework (QOF).

Data is presented in CSV files for the 2013/14 year onwards. For previous years, data is available in summary tables from the links provided.

The Quality and Outcomes Framework (QOF) is the annual reward and incentive programme detailing GP practice achievement results.

QOF is a voluntary process for all surgeries in England and was introduced as part of the GP contract in 2004. It is reported in two formats; this publication, and the on-line search function (www.qof.hscic.gov.uk)

QOF awards surgeries achievement points for:

• managing some of the most common chronic diseases, e.g. asthma, diabetes
• implementing preventative measures, e.g. regular blood pressure checks
• the extra services offered such as child health care and maternity services
• the quality and productivity of the service, including the avoidance of emergency admissions to hospital
• compliance with the minimum time a GP should spend with each patient at each appointment

Achievement information is based on practice level achievement againsts primary care indicators. Prevalence figures are based on numbers of patients on GP clinical registers for specific conditions. Exceptions data presents information on numbers of patients with specific clinical conditions who are not included in QOF indicator data used to measure achievement. There are a number of criteria to determine exception reported patients.

All data are presented at GP practice, CCG, Area Team, Region and England

Prevalence registers included: Atrial Fibrillation (AF) Asthma (AST) Cancer (CAN) Coronary Heart Disease (CHD) Chronic Kidney Disease (CKD) Chronic Obstructive Pulmonary Disease (COPD) Cardiovascular Disease - Primary Prevention (CVDPP) Dementia (DEM) Depression (DEP) Diabetes (DM) Epilepsy (EP) Heart Failure (HF) Heart Failure due to LVD (HF) Hypertension (HYP) Learning Disabilities (LD) Mental Health (MH) Obesity (OB) Osteoporosis (OST) Peripheral Atrial Disease (PAD) Palliative Care (PC) Rheumatoid Arthritis (RA) Smoking Indicators (SMOK) Stroke (STIA) Thyroid (THY)

Chronic Health Condition Prevalence in Stockport, UK, 2016

Counts of Hypertension, Anxiety, Diabetes and Other Chronic Health Conditions

By data.world's Admin [source]

About this dataset

This dataset contains crucial information regarding the prevalence of various health conditions affecting Stockport, UK, in June 2016. This dataset will help you better understand the prevalence rates of Hypertension, Anxiety, Depression, Asthma, Obesity, Diabetes, Coronary Heart Disease (CHD), Falls (both accidental and medical-related), Cancer (various forms listed), Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD) , Stroke/Trans-Ischaemic Attack and Atrial Fibrillation amongst individuals living in Lower Layer Super Output Areas across Stockport which are grouped by codes. The count of individuals affected by each condition cited is provided along with the GP Registered Population for each LSOA which typically ranges from 1000 to 2000 people per LSOA. This data could be utilized to identify areas most impacted by healthcare related issues from a geographical perspective as well as help provide insight into chronic illnesses that may require further attention throughout Stockport's communities

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

The data contained in this dataset consists of information on chronic health conditions gathered from Lower Layer Super Output Areas (LSOA) located in Stockport, UK for June 2016. The count information provided pertains to Hypertension, Anxiety, Depression, Asthma, Obesity, Diabetes, Coronary Heart Disease (CHD), Falls, Cancer and Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), Stroke/Trans-Ischaemic Attack and Atrial Fibrillation.

• To get a better understanding of what this dataset looks like we will start by reviewing the columns it contains. The columns contain information about: Lower Layer Super Output Area Code(lsoa11cd), Lower Layer Super Output Area Name(lsoa11nm & lsoa11nmw for Welsh language version) , GP Registered Population(GPRegPop), Hypertension (Hypertens), Anxiety(Anxiety), Depression(Depression) ect .

• To get an overview of what this dataset is about use a summary statistic tool such as mean(), median(), mode() etc to aggregate your data. This can be done by computing each column’s summary statistics separately or by combining them into one table for every condition listed here. This way you can obtain an overview which accurately reflects the overall population distribution pertaining to particular chronic health condition across multiple LSOA's at one time frame only.

• For deeper analysis refine your finding further or delve down into cause and effect make use graphs & charts such as scatter plots or line charts etc,. as well correlational analysis such Joint Analysis/Common Factor Analysis & Multiple Regression Analysis which will give you an insight into co-occurrence frequency or other related variables whcih could play a role in any particular health condition cause and affect outcomes over a period of time allowing further investigation if needed be pertaining suspected underlying causes regarding chronic medical conditions observed .

• Finally it is important that comprehensive datasets are created using wide range factors relevant local determinants before drawing conclusions so allow public bodies with decision making power make informed decisions accordingly when devising strategies for tackling causes associated with specific chronic medical coniditons target population groups required provide assistance towards public welfare goal become more efficient targeting

Research Ideas

• Analyzing the geographic variation of health conditions in Stockport in order to inform public health policy decisions. For example, to identify areas where specific interventions are needed to improve healthcare outcomes, or target resources at particular (at-risk) populations.
• Examining the correlations between different health conditions and identifying potential links or risk factors for developing one condition when another is present.
• Utilizing the GP registered population for each LSOA as a metric for predicting which areas of Stockport are likely to require additional funds or resources in order ensure adequate access to healthcare services for their residents

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

See the dataset description for more informat...

Most common CCS groups and chronic conditions as primary cause of initial hospitalization.

IntroductionThe demographic shift leads to a tremendous increase in age-related diseases, which are often chronic. Therefore, a focus of chronic disease management should be set on the maintenance or even improvement of the patients’ quality of life (QoL). One indicator to objectively measure QoL is the EQ-5D questionnaire, which was validated in a disease- and world region-specific manner. The aim of this study was to conduct a systematic literature review and meta-analysis on the QoL across the most frequent chronic diseases that utilized the EQ-5D and performed a disease-specific meta-analysis for treatment-dependent QoL improvement.Materials and methodsThe most common chronic disease in Germany were identified by their ICD-10 codes, followed by a systematic literature review of these ICD-10 codes and the EQ-5D index values. Finally, out of 10,016 independently -screened studies by two persons, 538 studies were included in the systematic review and 216 studies in the meta-analysis, respectively.ResultsWe found significant medium to large effect sizes of treatment effects, i.e., effect size >0.5, in musculoskeletal conditions with the exception of fractures, for chronic depression and for stroke. The effect size did not differ significantly from zero for breast and lung cancer and were significantly negative for fractures.ConclusionOur analysis showed a large variation between baseline and post-treatment scores on the EQ-5D health index, depending on the health condition. We found large gains in health-related quality of life mainly for interventions for musculoskeletal disease.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020150936, PROSPERO identifier CRD42020150936.

This statistic displays the prevalence of limiting long-standing illnesses among those older than 55 years of age in England in 2018/19, by gender and age. In this period, chronic illnesses were more prevalent in women in almost all groups compared to men.

Semi-structured interviews with 36 individuals with either type 1 or type 2 diabetes. The interviews address their diagnosis and current life with diabetes, their use of Facebook and consumption and production of online content in relation to diabetes and its impacts, if any, on their diabetes management.

Given the recognised importance of social networks in health and wellbeing, the recent rise in popularity of online networking sites affords a timely opportunity to learn more about their role in self-care associated with long-term conditions.

Focusing on diabetes as one of the most pressing healthcare priorities, and Facebook as currently the most popular social networking site, the project examines contextual factors that shape knowledge, attitudes and practices in relation to online networking and chronic illness.

The Facebook site allows its users to create textual and visual content, connections, organisational and individual pages, and groups, and in this way facilitates maintenance of different network types. Our study of Facebook use by people with diabetes, and by government and third sector organisations, will help us understand the role of these different networks, and of the Internet, in shaping and supporting self-care practices outside formal healthcare organisations.

The overall aim is to investigate systematically expert and lay perspectives on online networking and diabetes in the UK through the analysis of discourses and practices surrounding the use of Facebook. Methodologically, the project combines linguistic and sociological approaches and develops a framework for a critical and contextual study of online networking and health.

The Health Survey for England (HSE) monitors trends in the nation’s health and care. It provides information about adults aged 16 and over, and children aged 0 to 15, living in private households in England. The survey consists of an interview, followed by a visit from a nurse who takes some measurements and blood and saliva samples. Adults and children aged 13 to 15 were interviewed in person, and parents of children aged 0 to 12 answered on behalf of their children for many topics. Children aged 8 to 15 filled in a self-completion booklet about their drinking and smoking behaviour. A total of 8,178 adults (aged 16 and over) and 2,072 children (aged 0 to 15) were interviewed in the 2018 survey. 4,825 adults and 1,103 children had a nurse visit. Each survey in the series includes core questions, and measurements such as blood pressure, height and weight measurements and analysis of blood and saliva samples. In addition there are modules of questions on specific topics that vary from year to year. The detailed reports with supporting Excel tables can be found at the bottom of this page and comprise the following topics: Overweight and obesity in adults and children Asthma Adult's health-related behaviours (includes smoking, alcohol, fruit and vegetable consumption, physical activity and gambling) Longstanding conditions Adults' health (including diabetes, hypertension, and high cholesterol) Childrens' health (includes smoking, alcohol, and fruit and vegetable consumption) Social care in older adults _ This publication was updated on 31st January 2020. See the data quality statement attached to this page for more information.

This dataset forms part of the OPTIMising therapies, discovering therapeutic targets and AI-assisted clinical management for patients Living with complex multimorbidity (OPTIMAL) NIHR funded programme.

The dataset includes >40,000 adult patients with multimorbidity who were acutely admitted to hospital and had an inpatient stay. Longitudinal data includes serial physiology readings, frailty scores, blood results, medications, comorbidities, drug allergies, treatments, procedures and mortality outcomes up to a year post discharge.

Geography: The West Midlands (WM) has a population of 6 million & includes a diverse ethnic & socio-economic mix. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

All data uses should name both PIONEER and the NIHR Optimal programme in data outputs. This will be specified in the Data Licensing Agreement.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in OMOP and other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment (TRE) build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

BackgroundThe prevalence of multiple chronic conditions (MCC), defined as several coexisting chronic conditions, has increased with the aging of society. MCC is associated with poor outcomes, but most comorbid diseases in asthma patients have been evaluated as asthma-associated diseases. We investigated the morbidity of coexisting chronic diseases in asthma patients and their medical burdens.MethodsWe analyzed data from the National Health Insurance Service-National Sample Cohort for 2002–2013. We defined MCC with asthma as a group of one or more chronic diseases in addition to asthma. We analyzed 20 chronic conditions, including asthma. Age was categorized into groups 1–5 (< 10, 10–29, 30–44, 45–64, and ≥ 65 years, respectively). The frequency of medical system use and associated costs were analyzed to determine the asthma-related medical burden in patients with MCC.ResultsThe prevalence of asthma was 13.01%, and the prevalence of MCC in asthmatic patients was 36.55%. The prevalence of MCC with asthma was higher in females than males and increased with age. The significant comorbidities were hypertension, dyslipidemia, arthritis, and diabetes. Dyslipidemia, arthritis, depression, and osteoporosis were more common in females than males. Hypertension, diabetes, COPD, coronary artery disease, cancer, and hepatitis were more prevalent in males than females. According to age, the most prevalent chronic condition in groups 1 and 2 was depression, dyslipidemia in group 3, and hypertension in groups 4 and 5. Older age, low income, and severe disability were independent risk factors for MCC in patients with asthma. The frequency of asthma-related medical system use and asthma-associated costs increased with increasing numbers of coexisting chronic diseases.ConclusionComorbid chronic diseases in asthma patients differed according to age and sex. The asthma-related-medical burdens were highest in patients with five or more chronic conditions and groups 1 and 5.

EPIC-Oxford is the Oxford component of the European Prospective Investigation into Cancer and Nutrition (EPIC), a large multi-centre cohort study with participants enrolled from 10 European countries. The EPIC-Oxford study began in the 1990s and follows the health of 65,000 men and women living throughout the UK, many of whom are vegetarian. The main objective of EPIC Oxford is to examine how diet influences the risk of cancer, particularly for the most common types of cancer in Britain, as well as the risks of other chronic diseases.

EPIC-Europe was initiated in 1992. It involves over 500,000 people from 23 centres in 10 European countries. It is coordinated by the World Health Organization International Agency for Research on Cancer in Lyon, and supported by the European Union and national funding agencies.

EPIC-Oxford is one of two EPIC cohorts in the UK, the other is EPIC-Norfolk.

For further details on the study design, recruitment, data collection and other aspects of the EPIC-Oxford study, please visit https://www.ceu.ox.ac.uk/research/epic-oxford-1

A dataset providing GP recorded chronic obstructive pulmonary disease rates. Chronic Obstructive Pulmonary Disease (COPD) is a serious long-term lung disease in which the flow of air into the lungs is gradually reduced by inflammation of the air passages and damage to the lung tissue. Chronic Bronchitis and emphysema are common types of COPD. Chronic Obstructive Pulmonary Disease (COPD) is the fifth biggest killer disease in the UK, killing approximately 25,000 people a year in England. Further information For more information on public health, please visit: http://www.leeds.gov.uk/phrc/Pages/default.aspx

Smoking is a leading preventable cause of chronic diseases, including circulatory disease, cancer, and chronic lung conditions, and worsens outcomes in acute illnesses. Despite public health efforts, 13-16% of the UK population still smoke, with higher rates among hospital admissions, especially in older adults who also experience poorer outcomes.

Influenza can cause severe complications, such as ICU admission and death, particularly in older adults and those with chronic respiratory conditions. Smoking further increases the risks of mortality and ICU admission, yet UK-specific data on seasonal influenza in this context remains limited.

This dataset includes 13,524 influenza-related hospital admissions from January 2018 to July 2024, focusing on individuals aged 65 and older. It contains demographics, serial physiology, clinical assessments, diagnostic codes (ICD-10 and SNOMED-CT), initial presentations, ventilation, ICU transfers, prescriptions, and outcomes. While a dataset for all ages is available, this subset emphasizes older adults, who are at greater risk of severe complications, particularly from smoking.

Geography: The West Midlands has a population of 6 million & includes a diverse ethnic & socio-economic mix. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UHB runs a fully electronic healthcare record (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in OMOP and other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

Snapshot img

Hand Held Surgical Instruments Market Size 2024-2028

The hand held surgical instruments market size is forecast to increase by USD 2.85 billion at a CAGR of 8.09% between 2023 and 2028. Handheld surgical instruments have gained significant importance in the healthcare industry due to the increasing volume of surgeries driven by chronic conditions such as cancer, diabetes, and orthopedic disorders. Moreover, the demand for single-use surgical instruments is increasing due to the risks and complications associated with reusable instruments. In conclusion, the handheld surgical instruments market is expected to grow significantly due to the increasing volume of surgeries driven by chronic diseases and an aging population. The demand for single-use instruments is also increasing due to the risks associated with reusable instruments. the global supply chains for medical devices have been impacted by travel restrictions and the adoption of telemedicine, leading to increased demand for disposable incomes and healthcare expenditure. Key medical specialties, including cardiology, ophthalmology, wound care, and urology, are expected to drive the growth of the market.

Request Free Sample

The market is evolving with advancements in plastic surgery and non-surgical treatment options. While traditional hand-held instruments remain essential, innovations such as robotic-assisted surgery and image-guided interventions are enhancing precision and patient outcomes. The market is experiencing growth driven by the increasing prevalence of orthopedic ailments, as more individuals seek surgical solutions for musculoskeletal conditions. According to the OECD, the demand for these instruments is rising in both developed and emerging economies, where healthcare systems are increasingly adopting advanced surgical technologies. The surgical instruments continue to play a critical role in procedures, offering flexibility and control that complement robotic systems. With ongoing developments, the market is set to expand, supporting a range of medical disciplines from plastic surgery to orthopedic care.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals
  Ambulatory surgical centers
  Clinics
  Long-term care centers


Product

  Forceps
  Retractors
  Dilators
  Graspers and others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period. In the healthcare industry, hospitals serve as significant venues for conducting various surgical procedures, including those for chronic disorders. Multi-specialty hospitals, private institutions, and hospital groups collaborating with public and private entities are key market participants. The expansion of healthcare infrastructure is anticipated to fuel the growth of this sector. The proliferation of hospitals in developed and emerging economies, such as the US, China, and India, coupled with government initiatives to enhance hospital infrastructure, has led to an increase in surgical interventions for chronic conditions, including urological diseases, diabetes, cancers, and orthopedic deformities.

Additionally, elective surgical procedures, such as cardiovascular disorders treatment through cardiovascular surgery and breast surgery, are also common in hospitals. Surgeons play a crucial role in performing these procedures using handheld surgical instruments. The geriatric population's increasing need for orthopedic surgery further bolsters the market's growth.

Get a glance at the market share of various segments Request Free Sample

The hospitals segment accounted for USD 3.14 billion in 2018 and showed a gradual increase during the forecast period.

Regional Insights

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

In the global landscape, North America held a significant share of the market in 2023. This region's market growth can be attributed to several factors, including an aging population and the prevalence of chronic diseases. As per the Centers for Disease Control and Prevention (CDC), approximately 133 million Americans had one or more chronic conditions in 2020, with cardiovascular diseases (CVDs) and chronic respiratory diseases being the most common. Moreover, the incidence of colorectal cancer, ulcerative colitis, orthopedic sur

This dataset forms part of the OPTIMising therapies, discovering therapeutic targets and AI-assisted clinical management for patients Living with complex multimorbidity (OPTIMAL) NIHR funded programme.

Multimorbidity is common, especially in older adults, and is associated with an increased risk of hospital admissions and poorer outcomes. Caring for older adults with complex multimorbidity presenting acutely to hospital is challenging, as guidelines often do not focus on multimorbidity and older adults are especially susceptible to adverse effects from polypharmacy.

PIONEER has curated this dataset of 15,950 patients aged 65 and over with multimorbidity who were acutely admitted to hospital and had an inpatient stay. It contains longitudinal data on serial physiology readings, frailty scores, blood results, medications, comorbidities, drug allergies, treatments, procedures, and mortality outcomes up to a year post-discharge. While this subset focuses on older adults, a full dataset covering all ages is also available.

Geography: The West Midlands (WM) has a population of 6 million & includes a diverse ethnic & socio-economic mix. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UHB runs a fully electronic healthcare record (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

All data uses should name both PIONEER and the NIHR Optimal programme in data outputs. This will be specified in the Data Licensing Agreement.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in OMOP and other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

Uk Computed Tomography Market size was valued at USD 501.32 Million in 2024 and is projected to reach USD 877.59 Million by 2032, growing at a CAGR of 7.25 % from 2026 to 2032.

Uk Computed Tomography Market Drivers

Increasing Prevalence of Chronic Diseases: The rising incidence and mortality rates associated with chronic diseases like cancer, cardiovascular diseases, and neurological disorders significantly drive the demand for CT scans for diagnosis, staging, and monitoring. Aging Population: The UK's aging demographic is more susceptible to chronic conditions, leading to a greater need for diagnostic imaging services like CT. Technological Advancements: Continuous innovations in CT technology, including multi-slice CT, cone-beam CT, and AI-powered image analysis, offer improved image quality, faster scan times, and reduced radiation exposure, encouraging wider adoption. Growing Awareness and Emphasis on Early Diagnosis: Increased awareness among healthcare professionals and the public about the benefits of early disease detection through CT scans contributes to market growth. Government Initiatives and Healthcare Spending: Government investments in healthcare infrastructure and initiatives aimed at improving diagnostic capabilities, such as establishing new diagnostic centers and deploying more CT scanners across the NHS, are key drivers.

The Health Survey for England (HSE) is part of a programme of surveys commissioned by the Health and Social Care Information Centre. It has been carried out since 1994 by the Joint Health Surveys Unit of NatCen Social Research and the Research Department of Epidemiology and Public Health at UCL (University College London). The study provides regular information that cannot be obtained from other sources on a range of aspects concerning the public's health and many of the factors that affect health. The series of Health Surveys for England was designed to monitor trends in the nation's health, to estimate the proportion of people in England who have specified health conditions, and to estimate the prevalence of certain risk factors and combinations of risk factors associated with these conditions. The survey is also used to monitor progress towards selected health targets. Each survey in the series includes core questions and measurements (such as blood pressure, anthropometric measurements and analysis of blood and saliva samples), as well as modules of questions on specific issues that vary from year to year. In some years, the core sample has also been augmented by an additional boosted sample from a specific population subgroup, such as minority ethnic groups, older people or children; there was no boost in 2012. This is the 22nd annual Health Survey for England. All surveys have covered the adult population aged 16 and over living in private households in England. Since 1995, the surveys have included children who live in households selected for the survey; children aged 2-15 were included from 1995, and infants under two years old were added in 2001. Those living in institutions were outside the scope of the survey. This should be borne in mind when considering survey findings, since the institutional population is likely to be older and less healthy than those living in private households. The HSE in 2012 provided a representative sample of the population at both national and regional level. 9,024 addresses were randomly selected in 564 postcode sectors, issued over twelve months from January to December 2012. Where an address was found to have multiple dwelling units, a random selection was made and a single dwelling unit was included. Where there were multiple households at a dwelling unit, again one was selected at random. All adults and children in selected households were eligible for inclusion in the survey. Where there were three or more children aged 0-15 in a household, two of the children were selected at random to limit the respondent burden for parents. A nurse visit was arranged for all participants who consented. A total of 8,291 adults and 2,043 children were interviewed. A household response rate of 64 per cent was achieved. 5,470 adults and 1,203 children had a nurse visit. It should be noted that, as in 2011, there was no child boost sample in 2012. Thus the scope for analyses of some data for children may be limited by relatively small sample sizes.

Snapshot img

Patient Engagement Technology Market Size 2025-2029

The patient engagement technology market size is forecast to increase by USD 47.06 billion, at a CAGR of 21.6% between 2024 and 2029.

The market is experiencing significant growth, driven primarily by the increasing prevalence of chronic diseases and the digitization of healthcare. The rising number of chronic conditions necessitates more effective patient engagement strategies to manage care and improve outcomes. This trend is further fueled by the digitization of healthcare, enabling the adoption of technology solutions that facilitate remote monitoring, telehealth consultations, and patient education. However, market growth is not without challenges. Stringent regulations on patient engagement solutions pose a significant obstacle to market expansion. Compliance with data privacy laws and security regulations is essential to ensure patient data protection and maintain trust. Additionally, integrating these technologies with existing healthcare systems and workflows can be complex and costly, requiring substantial resources and expertise. Companies seeking to capitalize on market opportunities must navigate these challenges effectively, focusing on regulatory compliance, user-friendly designs, and seamless integration with healthcare providers' systems.

What will be the Size of the Patient Engagement Technology Market during the forecast period?

Request Free SampleThe market continues to evolve, driven by advancements in healthcare informatics and the integration of various technologies to enhance patient-centered care. Health data security remains a top priority as patient feedback and personal health records are increasingly digitized. Behavioral health integration, medication adherence, and appointment scheduling are seamlessly integrated into electronic health records, enabling value-based care and personalized health plans. Mobile technology plays a pivotal role in patient empowerment, with mobile health apps, user interface design, and user experience design enhancing health literacy and patient self-management. The Internet of Things (IoT) and wearable sensors provide real-time health data, enabling remote patient monitoring and care coordination platforms. Patient advocacy, data visualization, and community health resources further strengthen patient engagement strategies, while secure messaging, patient portals, and video conferencing facilitate patient-provider communication. Telehealth platforms and clinical decision support systems leverage data analysis and artificial intelligence to improve patient experience and chronic disease management. Natural language processing, data integration, and interactive health tools streamline healthcare consumerism and health information exchange, ensuring patient privacy and health information interoperability. The ongoing unfolding of market activities underscores the dynamic nature of patient engagement technology and its applications across various sectors.

How is this Patient Engagement Technology Industry segmented?

The patient engagement technology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. Delivery ModeOn-premise solutionWeb and cloud-based solutionEnd-userProvidersPayersIndividual usersComponentSoftwareServiceOthersTherapy AreaChronic diseasesFitnessWomen healthMental healthOthersApplicationSocial managementHome healthcare managementFinancial health managementOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyUKMiddle East and AfricaUAEAPACChinaIndiaJapanSouth AmericaBrazilRest of World (ROW)

By Delivery Mode Insights

The on-premise solution segment is estimated to witness significant growth during the forecast period.Patient engagement technology is a dynamic market characterized by the integration of various entities to enhance healthcare delivery and patient experience. Medication adherence, patient feedback, health data security, and behavioral health integration are integral components, ensuring effective patient-centered care. Electronic health records (EHRs) and mobile technology facilitate access to personalized health plans and empower patients with self-management tools. Value-based care strategies emphasize patient satisfaction and engagement through remote patient monitoring, education resources, and telehealth platforms. Healthcare informatics, care coordination platforms, and secure messaging streamline communication and data analysis. Wearable health devices and patient portals enable real-time data access, while video conferencing and appointment scheduling tools enhance convenience. Natural language processing and mobile health apps improve user experience and health literacy. Data visualization, community health resources, and health data i

According to Cognitive Market Research, the global Laboratory Centrifuge Market size will be USD 1962.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 630% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 726.24 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.1% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 569.21 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 471.07 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 74.59 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 78.51 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 43.18 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2033.
Microcentrifuges category is the fastest growing segment of the Laboratory Centrifuge industry

Market Dynamics of Laboratory Centrifuge Market

Key Drivers for Laboratory Centrifuge Market

Rise of Infectious Diseases to Boost Market Growth

The market for laboratory centrifuges is expanding due to the rise of infectious diseases. The global illness burden has increased as a result of diseases like SARS, the Zika virus, Ebola, and COVID-19, which have caused infections in many parts of the world. About 60% of known human pathogens and up to 75% of newly discovered human pathogens are thought to be zoonotic infectious agents, which are infectious illnesses of animals that develop to infect human hosts. By altering the geographic ranges of microorganisms and vectors, climate change is predicted to alter the epidemiology of infectious diseases significantly. Since microorganisms can adapt to higher temperatures, there is growing fear that as a result of global warming, microbes with greater heat tolerance may be selected for, potentially defeating human endothermy defenses and evolving the epidemiology of many diseases. Centrifuge systems are used in laboratories to purify cells, organelles, viruses, proteins, and nucleic acids. As a result, the market for laboratory centrifuges is driven by the rise in infectious diseases and the need for lab testing solutions.

Rising Prevalence of Chronic Illnesses to Boost Market Growth

The market for laboratory centrifuges is anticipated to continue developing as a result of the rising prevalence of chronic illnesses. Chronic diseases need constant care and management since they are long-term medical problems with enduring and frequently worsening symptoms. Laboratory centrifuges are used to separate blood components in chronic disorders, which helps with disease detection and management by enabling diagnostic tests. For instance, in April 2024, allergies affected over 21 million people in the UK, according to Allergy UK, a UK-based national charity. In 2022, allergies were the most common chronic health condition reported, and by 2026, half of Europe's population is expected to suffer from at least one allergy. Consequently, the market for laboratory centrifuges is being driven by the rising number of chronic disorders.

Restraint Factor for the Laboratory Centrifuge Market

High Initial and Continuing Maintenance Costs of Laboratory Centrifuges Will Limit Market Growth

The high initial and continuing maintenance costs of laboratory centrifuges continue to be a significant obstacle to industry growth. The cost of ownership is increased by the need for expensive repairs, frequent calibration, and a large initial investment for more sophisticated types, such as floor-standing centrifuges and ultracentrifuges. Further increasing the cost are automation features, temperature controls, and specialty rotors. Budget-constrained small and mid-sized labs, research institutes, and facilities in underdeveloped nations find these costs especially difficult to bear. The increasing need for centrifugation in pharmaceutical research,...

All data in this dataset has a UK Open Government Licence (OGL). OGL

Introduction

Organ donation and transplantation represent a critical component of modern healthcare, offering a second chance at life for patients suffering from end-stage organ failure. The practice of organ donation encompasses a wide range of benefits, not only for the recipients but also for the donors and society as a whole. This dataset, governed by the UK Open Government Licence (OGL), provides comprehensive insights into organ donation and transplantation activities in the UK. It highlights trends, benefits, and challenges associated with these life-saving procedures. The detailed statistics and visualisations offer a clear picture of how organ donation impacts healthcare outcomes, economic productivity, and societal health.

Organ donation and transplantation

Benefits for Recipients

• Life-Saving: Organ transplants can save lives. For patients with end-stage organ failure, transplantation can be the only option to survive.
• Improved Quality of Life: Recipients often experience a significant improvement in their quality of life. They can return to normal activities, work, and enjoy time with family and friends.
• Extended Lifespan: Transplants can significantly extend the lifespan of recipients. For example, a kidney transplant can add years to a patient's life compared to dialysis.
• Reduced Healthcare Costs: Although the initial costs of organ transplantation are high, long-term costs are often lower compared to ongoing treatments for organ failure, such as dialysis for kidney failure.

Benefits for Donors

• Living Donor Gratification: Living donors often feel a profound sense of satisfaction and fulfilment knowing they have saved a life.
• Legacy and Impact: Deceased donors leave a lasting legacy, giving others a chance at life and positively impacting many families.
• Altruism and Community Health: Donating organs can foster a sense of community and altruism, inspiring others to consider donation and promoting public health awareness.

Societal Benefits

• Reduced Burden on Healthcare System: Successful transplants reduce the long-term need for medical care, hospitalisations, and ongoing treatments, easing the burden on healthcare systems.
• Economic Productivity: Transplant recipients often return to work and contribute economically, benefiting society at large.
• Advancements in Medical Research: Organ donation promotes medical research and advancements in transplantation techniques, immunosuppression, and organ preservation, leading to overall improvements in healthcare.
• Public Awareness and Education: Organ donation programs raise awareness about the importance of health and medical science, encouraging preventive care and healthy lifestyles.

Specific Organ Transplants

• Kidney Transplant: Most common type, improving the lives of those with chronic kidney disease or failure. Reduces the need for dialysis.
• Liver Transplant: Vital for patients with liver failure or severe liver diseases. It can dramatically improve the recipient’s prognosis and quality of life.
• Heart Transplant: For patients with severe heart failure or heart disease, a transplant can be life-saving and greatly enhance life quality.
• Lung Transplant: Beneficial for individuals with severe respiratory diseases, improving breathing and overall health.
• Pancreas and Intestine Transplants: These are less common but essential for certain patients with diabetes or intestinal failure, significantly improving health outcomes.

Summary

Organ donation and transplantation are crucial in modern medicine, offering life-saving and life-enhancing benefits to recipients, profound fulfilment for donors, and significant advantages for society as a whole. Encouraging organ donation through education, awareness campaigns, and support for donor families can help address organ shortages and save more lives.

Original Table

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F13231939%2F4e452d20f121ac075aadd3adaefb71a3%2FScreenshot%202024-07-11%2011.25.52.png?generation=1720711079738748&alt=media" alt="">

The table provides detailed activity figures for organ donation and transplantation in the UK as of April 11, 2023. The table is divided into sections for organ donors and organ transplants, comparing the current year’s data (April 1, 2022, to March 31, 2023) with the previous year (April 1, 2021, to March 31, 2022) and pre-COVID year (April 1, 2019, to March 31, 2020). Here’s a breakdown:

Organ Donors

• Donors after brain death (DBD): Slight decrease from the previous year and a more significant decrease compared to the pre-COVID year.
• **Donors after circulato...